you are viewing a single comment's thread
view the rest of the comments

The sample size is more than sufficient to make these statements. The only flaw is that all participants are from Norway so there may be selection bias.

2200 people would be enough for a phase 3 clinical trial with a lot of participants. You know, the type of study after which your medication/treatment will be approved if successful:

Phase III studies are randomized controlled multicenter trials on large patient groups (300โ€“3,000 or more depending upon the disease/medical condition studied) and are aimed at being the definitive assessment of how effective the drug is, in comparison with current 'gold standard' treatment.

https://en.wikipedia.org/wiki/Phases_of_clinical_research

  • source
  • parent